# Christoph Broja

> Christoph Broja is a Series C investor at EQT Life Sciences backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners)
- Total investments: 2
- Last investment: Oct 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/christoph-broja-2420b81b7/

Christoph Broja is a Series C investor at EQT Life Sciences focused on Health Care and Biotechnology. Christoph Broja is based out of Germany, and is the a Partner at EQT Life Sciences. Christoph previously served as the Board Observer at Electra Therapeutics. Christoph Broja attended Friedrich Schiller University Jena. Christoph Broja is a certified Chartered Financial Analyst.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 100% |
| Series B | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $139.3M | Series B | Mar 14, 2024 |  |

2 of 2 investments shown.

## Co-investors
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 2 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 1 deal together
- [BioMedPartners](https://shizune.co/investors/profile/biomedpartners) — VC Fund, 1 deal together
- [coparion](https://shizune.co/investors/profile/coparion) — VC Fund, 1 deal together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together

## About EQT Life Sciences

VC Fund · Amsterdam, The Netherlands

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

5 contacts available at EQT Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christoph Broja | Partner | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | https://shizune.co/investors/profile/joachim-rothe |
| Daniela Begolo | Managing Director | https://shizune.co/investors/profile/daniela-begolo |
| Ellen Cordo | Chief Finance | https://shizune.co/investors/profile/ellen-cordo |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Christoph Broja invest in?

Christoph Broja invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 2 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Christoph Broja last invest?

The most recent investment recorded for Christoph Broja closed in Oct 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co